D. Ross Camidge
0000-0003-3430-3213
Publication & Citation Trends
Most Cited Works
Publications
994 total
171P Real-world treatment patterns and outcomes in US patients (pts) with neurotrophic tyrosine receptor kinase-positive (NTRK+) solid tumors
Cited by 0
Semantic Scholar
A Phase I Open-Label Study of Cediranib Plus Etoposide and Cisplatin as First-Line Therapy for Patients With Extensive-Stage Small-Cell Lung Cancer or Metastatic Neuroendocrine Non-Small-Cell Lung Cancer.
Cited by 2
Semantic Scholar
The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations
Cited by 11
Semantic Scholar
EPH49 Prevalence and Incidence of ROS1 and NTRK Rearrangements in Real-World Patients With Advanced Non–Small Lung Cancer in the United States
Cited by 0
Semantic Scholar
Comparison of First-Line Radiosurgery for Small-Cell and Non-Small Cell Lung Cancer Brain Metastases (Cross-FIRE). OA
Cited by 15
Semantic Scholar
Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. OA
Cited by 22
Semantic Scholar
Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancer OA
Cited by 3
Semantic Scholar
TRIDENT-1: A global, multicenter, open-label Phase II study investigating the activity of repotrectinib in advanced solid tumors harboring ROS1 or NTRK1-3 rearrangements.
Cited by 12
Semantic Scholar
Research Topics
Lung Cancer Treatments and Mutations
(674)
Lung Cancer Research Studies
(269)
Colorectal Cancer Treatments and Studies
(158)
Cancer Genomics and Diagnostics
(156)
Lung Cancer Diagnosis and Treatment
(112)
Frequent Co-Authors
Affiliations
AstraZeneca (United Kingdom)
Human Genome Sciences (United States)
University of North Carolina at Chapel Hill
Roche (Switzerland)
University of Maryland, Baltimore